Finerenone in Primary IgA Nephropathy: A Matched Case-Control Study
The combination of finerenone with RASi is associated with a greater reduction in urinary protein and potentially better stabilization of eGFR compared with RASi alone in IgAN patients. However, these findings require further validation in prospective studies.
Authors
- Jing Xu (ORCID: https://orcid.org/0000-0001-6785-9846)
- Jingyuan Xie (ORCID: https://orcid.org/0000-0002-5508-0664)
- Zijin Chen (ORCID: https://orcid.org/0009-0000-4075-1499)
- Qing Zhao (ORCID: https://orcid.org/0000-0001-7163-7779)
- Qianfeng Weng
- Zhaohui Wang (ORCID: https://orcid.org/0000-0002-4610-4687)
- Xiaofan Hu
- Xinyi Zhu (ORCID: https://orcid.org/0009-0006-8106-4277)
- Wen Du (ORCID: https://orcid.org/0000-0002-3361-088X)
- Yan Ouyang (ORCID: https://orcid.org/0000-0002-3181-8708)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1159/000546536
- Citations
- 4
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 5.72
Funders
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality